Time to screen for congenital toxoplasmosis?

Clinical Infectious Diseases

Volumn 42, Issue 10, 2006, Pages 1395-1397

  Kim, Kami ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIMETHAMINE; SULFADOXINE;

CHILD; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONGENITAL TOXOPLASMOSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EYE DISEASE; HEARING LOSS; HUMAN; MASS SCREENING; MOTOR DYSFUNCTION; NEWBORN SCREENING; NOTE; PRENATAL SCREENING; PRIORITY JOURNAL; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VISUAL IMPAIRMENT;

HUMANS; INFANT; INFANT, NEWBORN; MASS SCREENING; NEONATAL SCREENING; NEW ENGLAND; TOXOPLASMOSIS, CONGENITAL;

EID: 33646461684     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/501362     Document Type: Note

References (12)

1. McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: The National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis 2006; 42:1383-94 (in this issue).
2. McAuley J, Boyer KM, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994; 18:38-72.
3. Koppe IG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1986; 1:254-6.
4. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980; 66:767-74.
5. Desmonts G, Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. N Engl J Med 1974; 290:1110-6.
6. Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994;330:1858-63.
7. Lebech M, Andersen O, Christensen NC, et al. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Danish Congenital Toxoplasmosis Study Group. Lancet 1999; 353:1834-7.
8. Paul M, Petersen E, Pawlowski ZS, Szczapa J. Neonatal screening for congenital toxoplasmosis in the Poznan region of Poland by analysis of Toxoplasma gondii-specific IgM antibodies eluted from filter paper blood spots. Pediatr Infect Dis J 2000; 19:30-6.
9. Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999; 180:410-5.
10. Boyer KM, Holfels E, Roizen N, et al. Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening. Am J Obstet Gynecol 2005; 192:564-71.
11. Jara M, Hsu HW, Eaton RB, Demaria A Jr. Epidemiology of congenital toxoplasmosis identified by population-based newborn screening in Massachusetts. Pediatr Infect Dis J 2001; 20:1132-5.
12. Cook AJ, Gilbert RE, Buffolano W, et al. Sources of Toxoplasma infection in pregnant women: European multicentre case-control study. European Reserach Network on Congenital Toxoplasmosis. BMJ 2000; 321:142-7.